Revised SPCs: Votrient (pazopanib) 200 and 400 mg film coated tablets

SPC has been updated to warn of reports of tumour lysis syndrome (TLS) including fatal TLS, linked to use of pazopanib. It suggests preventative measures, such as treatment of high uric acid levels and IV hydration, should be considered prior to initiation of pazopanib.


electronic Medicines compendium